At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 24 enrolled
Drug / intervention
Vigamox Ophthalmic Solution +1 moredrug
Likely dose
Vigamox Ophthalmic Solution 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment
In Brief
A Phase 4 clinical trial evaluating Vigamox Ophthalmic Solution and BSS placebo for Bacterial Conjunctivitis. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The primary objective of this study is to investigate the initial antibiotic effects in the treatment of bacterial conjunctivitis symptoms in subjects one year of age and older.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Conjunctivitis
CountriesUnited States
CollaboratorsTopical Solutions Ltd.
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedNov 2008
Primary CompletionFeb 2009
TodayJul 2026
First PostedNov 26, 2008
Enrollment StartOct 1, 2008
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 17.6 years ago
Interventions
Vigamox Ophthalmic Solutiondrug
Moxifloxacin 5mg/mL 3 times daily for 7 days
BSS placebodrug
Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days